Search the Newsreel

NeuroOne Medical Technologies Corp (NMTC) (Q3 2026) Earnings Call Highlights: Revenue Grows 16% But Supply Chain Constraints Force Guidance Cut

NeuroOne Medical Technologies Corp (NMTC) reported a 16% increase in Q3 fiscal 2026 product revenue and strong order growth, with significant gross margin expansion. Despite positive developments like ISO 13485 certification and progress in drug delivery platforms, the company faced significant manufacturing and supply …

NMTC Q2 2026 Earnings: EPS Miss Widens Net Loss to -$0.28 Despite 1.86% Share Gain - Cost Structure Review

Here is Why Growth Investors Should Buy Globus Medical (GMED) Now

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a growth stock that can live up to its true potential can be a tough task. By their very …

Revolution Medicines stock hits all-time high at 208.77 USD

Revolution Medicines Inc. (RVMD) stock reached an all-time high of $208.77, currently trading at $208.48, reflecting a remarkable 468.97% increase over the past year. Despite being considered overvalued by InvestingPro analysis, the company closed Q2 with $3.9 billion in cash and investments and is …

Core Thesis on Lifecore Biomedical (LFCR): Monetizing Excess Production

Greenhaven Road Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund achieved an approximate 11% net return in the second quarter, indicating progress from the first quarter. Key changes to the …

Praxis Precision Medicines stock hits 52-week high at 388.27 USD

Praxis Precision Medicines (PRAX) stock has reached a new 52-week high of $388.27, marking a 721.64% increase over the past year with a market capitalization of $10.77 billion. Despite being unprofitable, this surge reflects investor confidence and recent positive developments, including a narrower-than-expected Q2 …

Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says

Contineum Therapeutics (CTNM), Disc Medicine (IRON), and Recursion Pharmaceuticals (RXRX) are making PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign …

Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $22

Morgan Stanley has reiterated its "Buy" rating on Generate Biomedicines (GENB.US), maintaining its target price at $22. This suggests a continued positive outlook on the company's stock performance from the financial institution.

TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX

Kahn Swick & Foti, LLC (KSF) has initiated an investigation into TransMedics Group, Inc. (NasdaqGM: TMDX) regarding potential breaches of fiduciary duties by its officers and directors. This follows a report by Scorpion Capital alleging fraudulent billing, coercive business practices, and unsafe organ transplantation, …

ICU Medical (ICUI): Buy, Sell, or Hold Post Q2 Earnings?

Parabilis Medicines (NASDAQ:PBLS) Sets New 1-Year High - What's Next?

China Medical System lifts H1 earnings as innovative drugs drive growth

China Medical System Declares Interim Dividend for First Half of 2026

China Medical System: Innovative products fueled double-digit growth, with strong R&D and global expansion momentum

Why Medicenna Therapeutics Corp stock surged yesterday

Is Revenue Growth Amid Margin Pressure Altering The Investment Case For Globus Medical (GMED)?

Globus Medical (GMED) reported second-quarter 2026 results with increased sales but a decline in net income and EPS, reaffirming its full-year revenue outlook. The company's investment case hinges on translating revenue growth into durable profits amidst integration and cost control challenges from acquisitions. While …

Resilient Fresenius Medical Care stock holds its ground as dividend and consensus support valuation

Fresenius Medical Care (FMS) stock closed at $23.75 on August 14, 2026, near the analyst consensus price target of $23.57, suggesting a fair valuation. The company offers an annual dividend of $0.61 per share, translating to a 2.57% yield with a payout ratio of …

Medical Properties Trust, Inc. Stock 12‑Month Price Target Cut to $5.11, Implies 22% Upside

Medical Properties Trust, Inc. (MPT) has seen its average 12-month price target reduced from $5.21 to $5.11 by analysts, with a range of $4.25 to $7 per share. This new target suggests a potential 22% upside from its August 14th closing price. The consensus …

IceCure Medical (NASDAQ: ICCM) director lists no shares

IceCure Medical Ltd. director David Salton filed an initial Form 3, reporting his status as a director of the company. This filing indicates no specific equity holdings, derivative positions, or transactions at this time, meaning David Salton does not currently report any direct or …

IceCure Medical : Initial Statement of Beneficial Ownership (Form 3)

This article reports that IceCure Medical (ICCM) director, David Salton, filed an Initial Statement of Beneficial Ownership of Securities (Form 3) with the SEC on August 17, 2026. This form indicates that Salton became a reporting person on August 12, 2026, due to his …

IceCure Medical (NASDAQ: ICCM) adds 73,890 RSUs to VP HR stake

IceCure Medical Ltd. (NASDAQ: ICCM) has granted 73,890 restricted share units (RSUs) to its VP Human Resources, Dotan Merav Nir, as a compensation-related equity award on August 14, 2026. This grant increases his total holdings to 76,168 ordinary shares and RSUs. The new RSUs …

IceCure Medical (ICCM) director Chan Vincent leaves board

IceCure Medical Ltd. (ICCM) director Chan Vincent Chun Hung has ceased serving on the board as of August 12, 2026. This departure means he is no longer subject to Section 16 reporting obligations, and no insider transactions were reported in connection with his exit. …

IceCure Medical (NASDAQ: ICCM) awards CFO 181K stock units at $0

IceCure Medical Ltd.'s CFO, Meir Peleg, was granted 181,483 restricted share units (RSUs) on August 14, 2026, at a price of $0.00 per share-equivalent. These RSUs have a vesting schedule where 25% vest on August 11, 2027, and the remaining 75% vest in twelve …

APYX Q2 2026 Earnings: Loss Narrower Than Expected as EPS Surprise Reaches 16.27% - Earnings Call Highlights

Profound Medical (NASDAQ: PROF) targets higher TULSA throughput

Profound Medical Corp. (NASDAQ: PROF) has introduced new real-time interventional MRI Treatment Delivery Consol (TDC) software for its TULSA-PRO® prostate ablation platform. This software aims to enhance procedural efficiency and physician experience, potentially increasing the number of TULSA Procedures™ per system per day from …

Some physicians report four TULSA procedures a day—what changes next?

Profound Medical (NASDAQ: PROF) has introduced new Treatment Delivery Consol (TDC) software for its TULSA-PRO® platform, aiming to increase procedural efficiency and allow surgeons to perform up to six TULSA Procedures™ per day. The upgrade enhances real-time interventional MRI control and physician-requested interface improvements, …

TYK Medicines Narrows Interim Loss as Other Income Surges Despite Higher R&D Spend

Insilico Medicine Included in MSCI Global Small Cap Indexes, Gaining Capital Market Endorsement in Core Strengths

CAMBRIDGE, Mass., Aug. 17, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), announced that it will be included in MSCI Global Small Cap Indexes compiled by Morgan Stanley Capital International (MSCI). The change …

BofA Securities Adjusts Medical Properties Trust Price Target to $4.25 From $5

BofA Securities has revised its price target for Medical Properties Trust (MPT) to $4.25, down from $5.00. This adjustment comes shortly after MPT announced it would maintain its quarterly dividend at $0.09 per share and completed a $2.4 billion note issuance for debt refinancing. …

Vivani Medical posts slide presentation under Reg FD; Exhibit 99.1 attached

Vivani Medical has filed an 8-K report, attaching a slide presentation as Exhibit 99.1. This presentation was distributed to the investment community and at conferences, providing key information about the company. The company notes that the presentation reflects information only as of the filing …

Form 8K PROFOUND MEDICAL CORP. For: 17 August By Investing.com

The article reports that Profound Medical Corp. filed a Form 8K on August 17. This filing is a standard requirement for public companies to announce major events that shareholders should know about. No specific details about the content of the 8K are provided in …

Themis Medicare updates Company Secretary and RTA contact emails

Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of TransMedics Group, Inc. (NASDAQ: TMDX) breached their fiduciary duties to shareholders. The firm encourages long-term shareholders to contact them to discuss potential legal rights and options, including corporate governance …

Medical Developments International Firms Ahead of FY26 Results — Is Penthrox Turnaround Finally Taking Hold?

Profound Medical (PROF) shifts CFO, ex-finance chief stays on as paid adviser

Profound Medical Corp. (PROF) has appointed Matthew Sobczyk as Interim Chief Financial Officer, effective August 14, 2026, following the resignation of Rashed Dewan. Dewan will receive a severance package and will provide transition and advisory services as a paid consultant until November 25, 2026. …

NeuroOne Medical (NMTC) Advances 6% to $1.94, Approaching Key Resistance - RSI Oversold Picks